| Target Price | €4.59 |
| Price | €2.91 |
| Potential |
57.73%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Heidelberg Pharma 2026 .
The average Heidelberg Pharma target price is €4.59.
This is
57.73%
register free of charge
€4.73
62.37%
register free of charge
€4.55
56.19%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend Heidelberg Pharma to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Heidelberg Pharma stock has an average upside potential 2026 of
57.73%
register free of charge
|
| Nov '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million € | 6.85 | 9.23 |
| 30.53% | 34.76% | |
| EBITDA Margin | -335.47% | -364.64% |
| 61.99% | 8.69% | |
| Net Margin | -282.92% | -320.48% |
| 37.08% | 13.28% |
4 Analysts have issued a sales forecast Heidelberg Pharma 2025 . The average Heidelberg Pharma sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Heidelberg Pharma EBITDA forecast 2025. The average Heidelberg Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Heidelberg Pharma Analysts have issued a net profit forecast 2025. The average Heidelberg Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Nov '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | -0.42 | -0.63 |
| 4.55% | 50.00% | |
| P/E | negative | |
| EV/Sales | 16.14 |
4 Analysts have issued a Heidelberg Pharma forecast for earnings per share. The average Heidelberg Pharma EPS is
This results in the following potential growth metrics and future valuations:
Heidelberg Pharma...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| PARETO SECURITIES AS |
Locked
➜
Locked
|
Locked | Sep 11 2025 |
| EQUI.TS |
Locked
➜
Locked
|
Locked | Jul 18 2025 |
| EQUI.TS |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| EQUI.TS |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| PARETO SECURITIES AS |
Locked
➜
Locked
|
Locked | Mar 27 2025 |
| PARETO SECURITIES AS |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
| PARETO SECURITIES AS |
Locked
➜
Locked
|
Locked | Oct 09 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
|
Sep 11 2025 |
|
Locked
EQUI.TS:
Locked
➜
Locked
|
Jul 18 2025 |
|
Locked
EQUI.TS:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
EQUI.TS:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
|
Mar 27 2025 |
|
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
|
Mar 26 2025 |
|
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
|
Oct 09 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


